Received Mar 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
received an extra dose today; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 58-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received a complete schedule on an unknown date). On 11-MAR-2025, the patient received the 3rd dose of Shingrix. On 11-MAR-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: received an extra dose today). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 11-MAR-2025 The medical assistant called to report a patient that received a complete schedule for Shingrix and received an extra dose today (on the day of reporting), which led to an extra dose administered. Medical assistant wanted guidance on this topic. No vaccine detail (lot number and expiration date) nor patient demographics were provided from the medical assistant's end. No further information was obtained or provided from the medical assistant's end in this call.